Amg 193

3 trials 1 recruiting

Filter these 3 trials by condition, phase, country and more.

Open in Search →

3 Registered trials

1 Recruiting

2 Completed trials

1 Sponsors

14 Countries

Phase II

Phase I/II

Phase I (FiH)

Phase II: 1 Phase I/II: 1 Phase I (FiH): 1

Oversight events:

2 corrective measures across 1 trial

View oversight register →

Indications tested

Non-small cell lung cancer 3 Biliary cancer metastatic 1 Ductal adenocarcinoma of pancreas 1

Sponsors using this IMP

All trials

3 total

A Phase 2 Study of AMG 193 in Subjects With MTAP-deleted Advanced NSCLC Recruiting

2024-514459-14-00 Phase II 12 countries Amgen Inc.
A phase 1/1b/2 study of AMG 193 alone and in combination with docetaxel in subjects with advanced MTAP-null solid tumors. Ended

2023-504363-17-00 Phase I (FiH) 4 countries Amgen Inc.
A Phase 1/2 Study of AMG 193 in Combination with IDE397 in Subjects with Advanced MTAP-null Solid Tumors Ended

2023-504364-42-00 Phase I/II 2 countries Amgen Inc.

Showing 1–3 of 3 trials

← All drugs A–Z